Mineralys Therapeutics' Treatment Fails to Reduce Sleep Apnea

Dow Jones03-10

By Katherine Hamilton

Mineralys Therapeutics said its drug lorundrostat didn't meaningfully reduce sleep apnea in a Phase 2 trial.

The biopharmaceutical company said Monday that the treatment didn't demonstrate a reduction in the Apnea-Hypopnea Index, which measures the number of times breathing stops or becomes shallow during an hour of sleep.

Shares fell 3%, to $26.35, in after-hours trading.

Lorundrostat did show meaningful reductions in blood pressure and had a meaningful safety profile, Chief Executive Jon Congleton said.

The trial involved 48 patients and lasted four weeks.

The Radnor, Pa., company also said the Food and Drug Administration accepted the new drug application for lorundrostat for the treatment of adult patients with hypertension in combination with other antihypertensive drugs.

The FDA has assigned a Prescription Drug User Fee Act target action date of Dec. 22.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

March 09, 2026 19:14 ET (23:14 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618608703?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-10 07:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618608703","market":"sg","top_or_hot":-1,"title":"Mineralys Therapeutics' Treatment Fails to Reduce Sleep Apnea","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Mineralys <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> said its drug lorundrostat didn't meaningfully reduce sleep apnea in a Phase 2 trial. \n</p>\n<p>\n  The biopharmaceutical company said Monday that the treatment didn't demonstrate a reduction in the Apnea-Hypopnea Index, which measures the number of times breathing stops or becomes shallow during an hour of sleep. \n</p>\n<p>\n  Shares fell 3%, to $26.35, in after-hours trading. \n</p>\n<p>\n  Lorundrostat did show meaningful reductions in blood pressure and had a meaningful safety profile, Chief Executive Jon Congleton said. \n</p>\n<p>\n  The trial involved 48 patients and lasted four weeks. \n</p>\n<p>\n  The Radnor, Pa., company also said the Food and Drug Administration accepted the new drug application for lorundrostat for the treatment of adult patients with hypertension in combination with other antihypertensive drugs. \n</p>\n<p>\n  The FDA has assigned a Prescription Drug User Fee Act target action date of Dec. 22. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 09, 2026 19:14 ET (23:14 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mineralys Therapeutics' Treatment Fails to Reduce Sleep Apnea</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMineralys Therapeutics' Treatment Fails to Reduce Sleep Apnea\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-03-10 07:14</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Mineralys <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> said its drug lorundrostat didn't meaningfully reduce sleep apnea in a Phase 2 trial. \n</p>\n<p>\n  The biopharmaceutical company said Monday that the treatment didn't demonstrate a reduction in the Apnea-Hypopnea Index, which measures the number of times breathing stops or becomes shallow during an hour of sleep. \n</p>\n<p>\n  Shares fell 3%, to $26.35, in after-hours trading. \n</p>\n<p>\n  Lorundrostat did show meaningful reductions in blood pressure and had a meaningful safety profile, Chief Executive Jon Congleton said. \n</p>\n<p>\n  The trial involved 48 patients and lasted four weeks. \n</p>\n<p>\n  The Radnor, Pa., company also said the Food and Drug Administration accepted the new drug application for lorundrostat for the treatment of adult patients with hypertension in combination with other antihypertensive drugs. \n</p>\n<p>\n  The FDA has assigned a Prescription Drug User Fee Act target action date of Dec. 22. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 09, 2026 19:14 ET (23:14 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2618608703","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618608703","pubTimestamp":1773098040,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Mineralys Therapeutics said its drug lorundrostat didn't meaningfully reduce sleep apnea in a Phase 2 trial.The biopharmaceutical company said Monday that the treatment didn't demonstrate a reduction in the Apnea-Hypopnea Index, which measures the number of times breathing stops or becomes shallow during an hour of sleep.Shares fell 3%, to $26.35, in after-hours trading.Lorundrostat did show meaningful reductions in blood pressure and had a meaningful safety profile, Chief Executive Jon Congleton said.The trial involved 48 patients and lasted four weeks.The Radnor, Pa., company also said the Food and Drug Administration accepted the new drug application for lorundrostat for the treatment of adult patients with hypertension in combination with other antihypertensive drugs.The FDA has assigned a Prescription Drug User Fee Act target action date of Dec. 22.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4007":"制药","MLYS":"Mineralys Therapeutics, Inc.","LENZ":"Therapeutics","BK4539":"次新股"},"translate_title":"Mineralys Therapeutics的治疗未能减少睡眠呼吸暂停","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1.5,"MLYS":0.9},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  Mineralys Therapeutics said its drug lorundrostat didn't meaningfully reduce sleep apnea in a Phase 2 trial. \n\n\n  The biopharmaceutical company said Monday that the treatment didn't demonstrate a reduction in the Apnea-Hypopnea Index, which measures the number of times breathing stops or becomes shallow during an hour of sleep. \n\n\n  Shares fell 3%, to $26.35, in after-hours trading. \n\n\n  Lorundrostat did show meaningful reductions in blood pressure and had a meaningful safety profile, Chief Executive Jon Congleton said. \n\n\n  The trial involved 48 patients and lasted four weeks. \n\n\n  The Radnor, Pa., company also said the Food and Drug Administration accepted the new drug application for lorundrostat for the treatment of adult patients with hypertension in combination with other antihypertensive drugs. \n\n\n  The FDA has assigned a Prescription Drug User Fee Act target action date of Dec. 22. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 09, 2026 19:14 ET (23:14 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618608703","isCrawlerRequest":true}